கல்லீரல் இதழ்

சுருக்கம்

A Review of Fatty Liver/NASH and Liver Cirrhosis: Genetics, Prevention, Nutritional, Behavioral Modification, Exercise, Pharmaceutical, Biophysics and Biotech Therapy

Trent W.Nichols Jr

This article reviews the current factors concerning obesity, metabolic syndrome or DM2 and the accumulation of fat which can result in fatty liver or steatohepatitis (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and cirrhosis. The pathophysiology is discussed as well as the current treatment and nutritional options of betaine, SAMe, phosphatidylcholine, silymarin with vitamin E and probiotics. Since obesity, metabolic syndrome and NAFLD/NASH are polygenic as well as epigenetic, the current nutritional, pharmaceutical and biotec solutions are fairly limited. Future options may include biophysical such as temperature control, light therapy ormelatonin and moderate magnetic field therapy capable of regulating over 2500 genes as well as novel can nabinoidagents and polyphenols.